EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinieOpen Access · CC BY 4.0

High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party

Ashika Ramamurthy, Elizabeth A Connolly, Jasmine Mar, Jeremy Lewin, Vivek A Bhadri, Marianne B Phillips, Mark Winstanley, Lisa M Orme, Peter Grimison, Joanna Connor, Smaro Lazarakis, Angela M Hong und 2 weitere

Cancer Treatment Reviews · 2024

DOI: 10.1016/j.ctrv.2024.102694 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2024. Verfasst von Ashika Ramamurthy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Concord Repatriation General Hospital, Sydney Local Health District, Concord, NSW 2139, Australia. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Rhabdomyosarcoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australia and New Zealand Sarcoma Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities. METHODS: A systematic review was conducted, using the population, intervention, comparison outcome (PICO) model, to evaluate whether utilization of HDT/ASCT impacts the outcome of patients with ES and RMS compared to standard chemotherapy alone, as part of first line treatment or in the relapse setting. Medline, Embase and Cochrane Central were queried for publications from 1990 to October 2022 that evaluated event-free survival (EFS), overall survival (OS), and toxicities. Each study was screened by two independent reviewers for suitability. A qualitative synthesis of the results was performed. RESULTS: Of 1,172 unique studies screened, 41 studies were eligible for inclusion with 29 studies considering ES, 10 studies considering RMS and 2 studies considering both. In ES patients with high-risk localised disease who received HDT/ASCT after VIDE chemotherapy, consolidation with melphalan-based HDT/ASCT as first line therapy conveyed an EFS and OS benefit over standard chemotherapy consolidation. Efficacy of HDT/ASCT using a VDC/IE backbone, which is now standard care, has not been established. Survival benefits are not confirmed for ES patients with metastatic disease at initial diagnosis. For relapsed/refractory ES, four retrospective studies report improvement in outcomes with HDT/ASCT with the greatest evidence in patients who demonstrate a treatment response before HDT, and in patients under the age of 14. In RMS, there is no proven survival benefit of HDT/ASCT in primary localised, metastatic or relapsed disease. CONCLUSION: Prospective randomised trials are required to determine the utility of HDT/ASCT in ES and RMS. Selected patients with relapsed ES could be considered for HDT/ASCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingRhabdomyosarcomaHematopoietic Stem Cell TransplantationHumansCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesProspective StudiesNew ZealandNeoplasm Recurrence, LocalTransplantation, AutologousTreatment Outcome

Stichwörter der Autor:innen

Autologous stem cell transplantEwing SarcomaGuidelinesHigh dose chemotherapyPaediatric oncologyRhabdomyosarcomaSarcoma

Autor:innen und Institutionen

  • Concord Repatriation General Hospital, Sydney Local Health District, Concord, NSW 2139, Australia.
  • Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW 2006 Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia.
  • Australia and New Zealand Sarcoma Association, Parkville, Victoria 3010, Australia.
  • Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Victorian Adolescent & Young Adult Cancer Service, Melbourne, VIC 3000, Australia.
  • Department Oncology, Haematology and Tissue & Cellular Therapies, Perth Children's Hospital, WA 6009, Australia; Telethon Kids Institute, Perth, WA 6009, Australia.
  • Starship Paediatric Blood and Cancer Centre, Central Auckland 1142, New Zealand.

Förderung

  • Australia and New Zealand Sarcoma Association

Zitieren

APA

Ramamurthy, A., Connolly, E. A., Mar, J., Lewin, J., Bhadri, V. A., Phillips, M. B., Winstanley, M., Orme, L. M., Grimison, P., Connor, J., Lazarakis, S., Hong, A. M., Omer, N., & Cayrol, J. (2024). High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2024.102694

Vancouver

Ramamurthy A, Connolly EA, Mar J, Lewin J, Bhadri VA, Phillips MB, et al. High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party. Cancer Treatment Reviews. 2024. doi:10.1016/j.ctrv.2024.102694

BibTeX
@article{Ramamurthy2024,
  author = {Ramamurthy, Ashika and Connolly, Elizabeth A and Mar, Jasmine and Lewin, Jeremy and Bhadri, Vivek A and Phillips, Marianne B and Winstanley, Mark and Orme, Lisa M and Grimison, Peter and Connor, Joanna and Lazarakis, Smaro and Hong, Angela M and Omer, Natacha and Cayrol, Julie},
  title = {High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party},
  journal = {Cancer Treatment Reviews},
  year = {2024},
  doi = {10.1016/j.ctrv.2024.102694}
}
Kostenlos starten →